GSK Paxil Patent Delistings Open Door For Generic Paroxetine Approvals
Executive Summary
GlaxoSmithKline's delisting of three Paxil patents will clear the way for approval of generic versions of the antidepressant, and set up a potential dispute over how 180-day exclusivity will be awarded
You may also be interested in...
Synthon Pexeva To Launch At 20% Discount To Generic Paxil; GSK Suit Settled
Synthon will launch Pexeva (paroxetine mesylate) during the first half of the year at a 20% discount to generic versions of Paxil (paroxetine hydrochloride)
Synthon Pexeva To Launch At 20% Discount To Generic Paxil; GSK Suit Settled
Synthon will launch Pexeva (paroxetine mesylate) during the first half of the year at a 20% discount to generic versions of Paxil (paroxetine hydrochloride)
GSK/Par Paxil Generic Deal Upheld In Court; FTC Closes Patent Investigation
GlaxoSmithKline's "authorized" generic Paxil agreement with Par does not raise any antitrust concerns, Chicago federal court Judge Richard Posner ruled Oct. 29